- Grace Dy and Eunice Wang are co-authors on 2 separate major studies
- Philip McCarthy to chair Plasma Cell Dyscrasia session
- Kara Kelly to speak at panel on Hodgkin lymphoma treatment options
BUFFALO, N.Y. — At the American Society of Clinical Oncology (ASCO) 2021 virtual Annual Meeting, which opens tomorrow, Roswell Park Comprehensive Cancer Center teams will share new data and insights on topics ranging from reducing use of opioids to manage patients’ pain following surgery to an analysis of trends in response to cancer treatment among patients of different races.
Roswell Park fellow Jason Ricciuti, MD, has been invited to give a talk during a Clinical Cancer Symposium on a pioneering study at Roswell Park that assessed the effects of prescribing fewer opioids to patients undergoing surgery. His presentation, Less is more: Postoperative pain management using restrictive opioid protocols in all surgical services in a comprehensive cancer center (abstract 103), part of the Novel Initiatives to Address Disparities in Cancer session, which begins at 10:30 a.m. EDT on Saturday, June 5, will feature an update on this ongoing research project led by Emese Zsiros, MD, PhD, FACOG, Associate Professor of Oncology in the Department of Gynecologic Oncology.
Song Yao, PhD, a molecular epidemiologist and Professor of Oncology in Roswell Park’s Department of Cancer Prevention and Control, will highlight collaborative work with Kaiser Permanente Northern California on relationships between blood levels of vitamin D and breast cancer outcomes in a large prospective cohort of breast cancer survivors. He will highlight the team’s findings in a poster discussion session beginning at 9 a.m. EDT Friday, June 4. The presentation is Clinically sufficient vitamin D levels at breast cancer diagnosis and survival outcomes in a prospective cohort of 3,995 patients after a median follow-up of 10 years (abstract 10510).
Researchers will highlight findings of several Roswell Park-led projects in virtual poster presentations during the meeting:
- Abhay Singh, MD, MPH, a fellow in Hematology and Medical Oncology at Roswell Park, will present Mutant PPM1D and TP53 populate the hematopoietic compartment after peptide receptor radionuclide therapy (PRRT) exposure (abstract 10605).
- Othman Akhtar, MBBS, Hematology-Oncology Fellow, will present Evaluating the role of baseline geriatric assessment in predicting adherence to oral targeted therapies and outcomes in older adults with non-Hodgkin lymphoma (abstract 12043 — work led by Senior Author Pallawi Torka, MD, Assistant Professor of Oncology.
- Ankita Kapoor, MD, of Rochester General Hospital will present work led by Shipra Gandhi, MD, Assistant Professor of Oncology, titled Factors associated with successful publication of abstracts in women malignancies: Are we closing the gender gap? (abstract 11034).
- Dharmesh Gopalakrishnan, MD, will present research he earned a 2021 ASCO Annual Meeting Merit Award for, working in collaboration with Senior Author Saby George, MD, FACP, Professor of Oncology and Medicine. The presentation is Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study (abstract 4568).
- Masanori Oshi, MD, a postdoctoral Research Scholar in the lab of Kazuaki Takabe, MD, PhD, FACS, Chief of Breast Surgery, will present their research Association of allograft rejection response score with biological cancer aggressiveness and with better survival in triple-negative breast cancer (TNBC) (abstract 561).
- Radiation Medicine resident physician Sung Jun Ma, MD, will present two projects he earned 2021 ASCO Annual Meeting Merit Awards for, working in collaboration with Senior Author Anurag Singh, MD, Professor of Oncology. The presentations are Racial differences and trends in pathologic complete response following neoadjuvant chemotherapy for breast cancer (abstract 575) and Evaluation of risk-stratification using gene expression assays in patients with breast cancer receiving neoadjuvant chemotherapy (abstract 576).
- Igor Puzanov, MD, MSCI, FACP, Senior Vice President for Clinical Investigation and Chief of Melanoma, will present A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors (abstract 2556). Read more about this research in this press release from ADC Therapeutics SA.
In addition to those Roswell-led presentations, two Roswell Park faculty leaders are co-authors of major studies to be presented during ASCO 2021, and two others will speak as session moderators or presenters:
- Kara Kelly, MD, Chair of the Roswell Park Oishei Children’s Cancer and Blood Disorders Program, was invited to share remarks as part of the case-based panel “Treatment Approaches for Hodgkin Lymphoma at Diagnosis and Relapse,” beginning Friday, June 4 at 9 a.m. EDT.
- Philip McCarthy, MD, interim Co-Chair of Medicine and Director of Transplant and Cellular Therapy, will chair the oral abstract session Hematologic Malignancies—Plasma Cell Dyscrasia, beginning Tuesday, June 8, at 8 a.m. EDT.
- Grace Dy, MD, Chief of Thoracic Oncology, is a co-author on Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS G12C mutated non-small cell lung cancer (abstract 9003), to be presented in an oral abstract session that begins Friday, June 4, at 1 p.m. EDT.
- Eunice Wang, MD, Chief of Leukemia, is a co-author on Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia (abstract 7008), to be presented in an oral abstract session that begins Friday, June 4, at 2:30 p.m. EDT.
Stay tuned to the Roswell Park online newsroom over the coming days for additional information about five of these ASCO 2021 research presentations.
###
This press release is also available on the Roswell Park website: https://www.roswellpark.org/newsroom/202106-roswell-park-researchers-gear-asco-2021-annual-meeting
Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.
